A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms




TekijätChalandon, Yves; Eikema, Diderik-Jan; Moiseev, Ivan Sergeevich; Ciceri, Fabio; Koster, Linda; Vydra, Jan; Passweg, Jakob R; Rovira, Montserrat; Ozcelik, Tulay; Gedde-Dahl, Tobias; Kröger, Nicolaus; Potter, Victoria; Yakoub-Agha, Ibrahim; Rambaldi, Alessandro; Itälä-Remes, Maija; Tanase, Alina D; Onida, Francesco; Gurnari, Carmelo; Scheid, Christof; Drozd-Sokolowska, Joanna; Raj, Kavita; McLornan, Donal P; Robin, Marie

KustantajaElsevier

Julkaisuvuosi2024

JournalBlood Advances

Tietokannassa oleva lehden nimiBlood advances

Lehden akronyymiBlood Adv

Vuosikerta8

Numero18

Aloitussivu4792

Lopetussivu4802

ISSN2473-9529

eISSN2473-9537

DOIhttps://doi.org/10.1182/bloodadvances.2024013468

Verkko-osoitehttps://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024013468/517033/Unrelated-donor-transplantation-with-post

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/457243588


Tiivistelmä
Prospective randomized trials have reported a benefit for anti-thymocyte globulin (ATG)-based graft-versus-host disease (GvHD) prophylaxis in the setting of allogeneic hematopoietic stem cell transplantation (Allo-HSCT) with unrelated donors (UD). However, the optimal GvHD prophylaxis strategy has been recently challenged by the increasing use of post-transplant cyclophosphamide (PTCY). We report from the EBMT registry the outcomes of 960 patients with myelodysplastic neoplasms (MDS) undergoing allo-HSCT from UD with PTCY or ATG as GvHD prophylaxis. Primary outcomes were overall survival (OS) and progression-free survival (PFS). Disease characteristics were similar in both groups. Day 28 neutrophil engraftment was significantly better with ATG (93% vs 85%, p<0.001). With a median follow-up of 4.4 years (95% confidence interval [CI] 4.2 - 4.8), 5-year OS was 58% (95% CI 50-65) with PTCY and 49% (95% CI 46-53%) in the ATG group, p=0.07. 5-year PFS was higher for PTCY with 53% (95% CI 45-60) vs 44% (95% CI 40-48) for ATG, p=0.043. Grade II-IV aGvHD incidence was lower using PTCY (23% [95% CI 17-29%] vs 30% [95% CI 27-33%]), p=0.044 while there was no difference in incidence of cGvHD at 5 years. Multivariable analyses confirmed better OS and PFS with PTCY, with a HR for ATG of 1.32 (1 - 1.74), p=0.05, and a better PFS for PTCY with a HR for ATG of 1.33 (1.03 - 1.73), p=0.03. This study suggests that GvHD prophylaxis using PTCY instead of ATG in this setting remains a valid option. Further prospective randomized studies would be essential to confirm these results.

Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2025-27-01 at 19:41